Article Complete
AIM
Tech Mahindra, Wipro Individually Partner With NVIDIA at GTC 2025
Tech Mahindra, Wipro Individually Partner With NVIDIA at GTC 2025
Sovereign Synergy Showdown

Tech Mahindra, Wipro Individually Partner With NVIDIA at GTC 2025

While Tech Mahindra aims to enhance drug safety with NVIDIA, Wipro has launched sovereign AI services.

Published Updated

Key takeaways

  • Tech Mahindra collaborates with NVIDIA to enhance drug safety through autonomous pharmacovigilance solutions.
  • The AI system aims to reduce human error and improve efficiency in drug safety management.
  • Implementing the solution can decrease turnaround times by 40% and operational costs by 25%.
  • Wipro also partners with NVIDIA, launching sovereign AI services at GTC 2025.
  • The collaboration emphasizes the transformative potential of AI in pharmaceutical data management.
5 min

Tech Mahindra and NVIDIA have announced a collaboration to develop an autonomous pharmacovigilance solution for improving drug safety management. According to the company blog, the solution uses Tech Mahindra’s TENO framework alongside NVIDIA AI Enterprise software, including NeMo, NIM microservices, and AI Blueprints.

The solution is being showcased at NVIDIA's GTC 2025.

“AI is ideal for monitoring medicines throughout their lifecycle to support safety. Integrating AI into the Tech Mahindra TENO framework with NVIDIA AI Enterprise software enhances pharmacovigilance by augmenting human capabilities to help identify potential safety issues more effectively,” said John Fanelli, vice president of enterprise software at NVIDIA.

The goal is to reduce the risk of human error. The AI system automates pharmacovigilance workflows, handling case intake, data transformation, quality control, and compliance management. In this system, AI agents classify, prioritise, and verify pharmacovigilance emails. 

According to the companies, the solution can reduce turnaround times by up to 40%, increase data accuracy by 30%, and lower operational costs by 25%. The system processes adverse drug reaction (ADR) cases and supports regulatory compliance through autonomous decision-making.

Nikhil Malhotra, chief innovation officer at Tech Mahindra, said the collaboration with NVIDIA will help the pharmaceutical industry manage large volumes of data more efficiently. By applying generative AI and multi-agent systems, they will improve drug safety.

“Together, we are revolutionising drug safety management and using the innovative AI-driven framework to develop multiple use cases for our global customers,” Malhotra said 

Alongside Tech Mahindra, Wipro has also launched sovereign AI services with NVIDIA to help governments and businesses develop country-specific AI solutions. The services use Wipro’s WeGA Studio and NVIDIA AI software to support local language models, data privacy, and AI governance. The applications include healthcare, banking, education, and emergency services, focusing on data security and sovereignty.

Membership

Stay ahead with AI insights.

Unlimited access to premium articles, exclusive analysis, and the stories shaping India's AI economy.

Subscribe now

AIM Americas

1190 Miraloma Way Suite P, Sunnyvale, CA 94085

AIM India

1st Floor, Sakti Statesman, Bellandur, Bengaluru – 560103

© 2026 AIM. All rights reserved.